Enzypep’s management team consists of Peter van Tilburg (CEO), Peter Quaedflieg (CSO) and Timo Nuijens (Lead Scientist) offering access to a wealth of knowledge on peptide R&D, process development and scale up. The Scientific Advisory Board consists of Dr. Rinus Broxterman, Dr. Roland Callens, Dr. Paul ten Kortenaar, Dr. Rodney Lax and Prof. Dr. Dick Janssen. This team incorporates a strong mix of entrepreneurial power, industrial oligopeptide manufacturing expertise and scientific and operational proficiency. Supported by a skilled staff Enzypep has the required human capital to achieve the business objectives.
Timo Nuijens graduated in Drug Innovation at the University of Utrecht. He performed his Ph.D. project on enzymatic peptide synthesis within DSM Innovative Synthesis B.V. (Geleen) under the supervision of Dr. Peter Quaedflieg (DSM Innovative Synthesis B.V.) and Prof. Rob Liskamp (Univ. Utrecht). His Ph.D. was obtained in May 2012. Since mid 2012 he is working as a lead scientist at Enzypep and has the responsibility of the scientific development and co-ordinating the R&D team in Geleen.
Peter Quaedflieg graduated from Eindhoven University in Chemical Engineering in 1988 and obtained a Ph.D. degree in Organic Chemistry with Prof. Jacques van Boom at Leiden University (The Netherlands) in 1993. In that year he joint DSM where he held various positions in R&D and process development. Currently he is Principal Scientist Route Scouting and Science Team Leader Organic Chemistry at DSM Innovative Synthesis in Geleen (The Netherlands). His research interests cover the synthesis of chiral pharmaceutical intermediates and peptides and the use of enzymes in organic and polymer synthesis.
Peter van Tilburg
Peter van Tilburg studied organic chemistry and worked for 12 years at DSM in different positions from process R&D, project management and new business development. In 1999 co-founded ChemShop and build the company from scratch to a very successful Process R&D and scale up company in the position of CEO. In 2007 successfully initiated an exit scenario by selling the company to Cambridge Major Laboratories US. Since 2007 continued as CEO of CML-Europe BV and build the company to one of the best FDA approved Process R&D and scale up companies for API’s in the world with app. 80 people at the site in the Netherlands. His knowledge of appropriate level of cGMP is profound. As of 2010 he is acting as a private investor and holds investments in several companies. In 2012 he founded Enzypep BV and retired from CML Europe April 2014.
Ana Toplak received her M.Sc. degree in 2006 from the Chemistry Department at the University of Zagreb (Croatia). After graduation she worked for GlaxoSmithKline R&D in Zagreb as medicinal chemist. In 2008, she joined the group of prof. dr. Dick B. Janssen at the University of Groningen (the Netherlands) where she will receive her PhD degree in 2016 in enzyme engineering focusing on the development of enzymes for peptide ligation. Since July 2015 she is lead biochemist at Enzypep B.V.
Marcel Schmidt graduated in chemical biology at the University of Bielefeld (Germany). After undergraduate research with Prof. Dr. Tom N. Grossmann at the Chemicals Genomics Center of the Max Planck Society (Dortmund, Germany), he performed graduate research with Prof. Dr. Martin Schmeing at McGill University (Montreal, Canada) and Prof. Dr. Norbert Sewald at the University of Bielefeld. His research interests strongly focusses on new, innovative (bio)-conjugation techniques for peptides and its applications. In 2015 he joined EnzyPep (Geleen, The Netherlands) and is currently pursuing his PhD within EnzyPep under the supervision of Prof. Dr. Jan van Maarseveen (University of Amsterdam). His work focusses on the development of enzyme-mediated peptide ligation methodologies and its application to the synthesis of complex cyclic peptides.
Rowin de Visser
Rowin de Visser graduated as a Master of Science in Biomedical Engineering from the University of Technology in Eindhoven. After performing undergraduate research at at the University of Queensland (Brisbane, Australia) with a focus on native chemical ligation of peptidic toxins she did her master research project in the field of chemical biology (small molecule inhibition of nuclear receptors). As of June 2017 she joined the EnzyPep team as a research chemist.
Michel Goldbach obtained his Bachelor of Science in Chemistry in 2012 at the Zuyd University of Applied Sciences in Heerlen. After graduating he worked as an associate scientist for DSM Innovative Synthesis B.V. for almost two years. In 2013 he started a master’s in drug innovation at the University of Utrecht. During this time he worked as a scientist at CRB Benelux B.V. in Maastricht, mainly focusing on the synthesis of active cosmetic ingredients. In 2014 he started an internship at EnzyPep B.V. where, after graduating, he started working fulltime in April 2016.
Linda Meekels received her Bachelor of Science in Biomedical and Biochemical research in 2010 at Zuyd University of Applied Sciences in Heerlen. With a strong interest in biochemistry and biocatalysis, she completed her pre-master in biotechnology at the University in Groningen in 2011. After her graduation she worked as a genetic laboratory technician at the Maastricht University Hospital for about 6 years. As of April 2017 she joined EnzyPep's biochemistry group.